News
09-18-2015, 05:03 AM
PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.
More... (http://www.news-medical.net/news/20150918/PharmaMar-begins-phase-II-Basket-trial-to-evaluate-safety-efficacy-of-PM1183-in-advanced-solid-tumors.aspx)
More... (http://www.news-medical.net/news/20150918/PharmaMar-begins-phase-II-Basket-trial-to-evaluate-safety-efficacy-of-PM1183-in-advanced-solid-tumors.aspx)